ProAgio for advanced pancreatic cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called ProAgio combined with standard chemotherapy for people with stage IV pancreatic cancer. It aims to see if the combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have stage IV pancreatic cancer that has spread.
- You have not had gemcitabine and nab-paclitaxel before.
- You are healthy enough to undergo a biopsy of your tumor.
- Your cancer can be measured on scans (RECIST criteria).
- You are in good physical condition (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, an immunotherapy drug (adebrelimab) and a chemotherapy regimen (NALIRIFOX) before any surgery, for people with locally advanced pancreatic cancer. The goal is to shrink the tumor enough to make surgery possible, potentially improving outcomes.
This trial tests a new drug called ProAgio combined with the chemotherapy gemcitabine for people with triple-negative breast cancer that has spread to other parts of the body. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a new combination of drugs (ATRA, SDK002, chemotherapy, and an immunotherapy) for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a new drug (OMTX705) combined with standard chemotherapy (gemcitabine/nab-paclitaxel) and an immunotherapy (tislelizumab) for people with advanced pancreatic cancer. It may be an option if you have had little or no prior chemotherapy.
This trial tests a new drug (BMS-986340) plus standard chemo for people whose pancreatic cancer has spread or come back. The goal is to see if this combination works better.
This trial tests a new combination of a migraine drug (rimegepant) with standard chemotherapy (AG) as a first treatment for advanced pancreatic cancer. It aims to see if this combo can help shrink tumors or slow the cancer.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.